Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001.

Slides:

Advertisements

Similar presentations

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Advertisements

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2- positive early breast cancer (PHARE): a randomised phase 3 trial Speaker: 陳鴻明.

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

Anastrozole (‘Arimidex’): a new standard of care?

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.

Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.

Number of brain metastasis

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

Figure 1. Mesothelioma mortality in The Netherlands 1997–2002 (source: Netherlands National Institute of Statistics). From: Occupational asbestos exposure:

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.

Volume 18, Issue 7, Pages (July 2017)

Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 2. A consort diagram showing the flowchart of the trial

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

The Evolving Standard of Care in Gastric Cancer

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

European Cooperative Trial in Operable Breast Cancer(ECTO): Improved freedom from progression from adding paclitaxel(T) to doxorubicin(A) followed by CMF.

Volume 19, Issue 2, Pages (February 2018)

Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results.

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.

Untch M et al. Proc SABCS 2010;Abstract P

Baselga J et al. SABCS 2009;Abstract 45.

chemotherapy for patients with MC versus those with AC

George E. Kikano, MD, Marie T. Brown, MD Mayo Clinic Proceedings

Volume 13, Issue 11, Pages (November 2012)

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Progesterone receptor nuclear morphology patterns in breast cancer.

The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis P.C. Minneci, K.J. Deans, P.Q. Eichacker, C. Natanson

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Plot with best overall response and study duration.

Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review Gennaro D’Amico, Juan Carlos Garcia-Pagan,

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Volume 9, Issue 4, Pages (April 2008)

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

Volume 19, Issue 2, Pages (February 2018)

Masatsugu Hamaji, MD, Syed Osman Ali, MD, Bryan M. Burt, MD

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Volume 11, Issue 3, Pages (March 2010)

Volume 371, Issue 9618, Pages (March 2008)

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Helen Barraclough, MSc, Ramaswamy Govindan, MD

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Published online Feb 7, 2019 Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling:

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

Heterogeneity in the natural history of triple negative breast cancer.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Fig. 2. Forest plot of the meta-analysis for homocysteine levels

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Presentation transcript:

Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology

Figure 2. (a) RFS all 885 patients; (b) OS all 885 patients. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology

Figure 3. (a) RFS HER-neg patients; (b) OS HER-neg patients. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology

Figure 4. (a & b) Forest plots subgroup analyses HER2/neg tumours Figure 4. (a & b) Forest plots subgroup analyses HER2/neg tumours. These Forest plots show the effect of high-dose therapy on the hazard ratio for relapse (or death) and the 99% confidence interval. The size of the solid squares corresponds to the size of the subgroups. Subgroups for which the line representing the 99% confidence interval lies to the left of the vertical line represent subgroups for which high-dose chemotherapy may offer a significant benefit over conventional therapy with respect to RFS. The diamonds correspond to the 95% confidence intervals. ER: oestrogen receptor; PR: progesterone receptor; MAI: mitotic activity index. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology

Figure 5. RFS in patients with HER2/neu-negative and hormone receptor-negative tumours. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4):588-596. doi:10.1093/annonc/mdl001 Ann Oncol | © 2006 European Society for Medical Oncology